Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › URGN

SILVERARC CAPITAL MANAGEMENT, LLC position in URGN

UROGEN PHARMA LTD · Health Care

SILVERARC CAPITAL MANAGEMENT, LLC reported holding 1,148,689 shares of URGN (UROGEN PHARMA LTD) in its Q3 2026 13F filing — a position valued at US$46.7M, representing 5.95% of its reported portfolio and ranking #4 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed URGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.15M sh
Reported value held$46.67M
Portfolio Weight5.95%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How SILVERARC CAPITAL MANAGEMENT, LLC's URGN position evolved

SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in URGN in Q3 2023 at 508,883 shares (US$7.1M). The position peaked in Q2 2026 at 1,301,979 shares, worth US$47.9M. Across 13 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 6 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,148,689 shares valued at US$46.7M — a reduction of -153,290 shares quarter over quarter.. Notable position changes include a 117% increase in Q2 2024 (shares fell 24% over the following quarter), a 46% increase in Q2 2025 (shares rose 46% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 508.88K $7.13M New
Q4 2023 525.40K $7.88M Add
Q1 2024 508.59K $7.63M Reduce
Q2 2024 1.10M $18.49M Add
Q3 2024 901.13K $11.44M Reduce
Q4 2024 1.12M $11.93M Add
Q1 2025 1.38M $15.28M Add
Q2 2025 2.02M $27.71M Add
Q3 2025 1.58M $31.47M Reduce
Q4 2025 1.74M $40.72M Add
Q1 2026 1.50M $27.02M Reduce
Q2 2026 1.30M $47.91M Reduce
Q3 2026 1.15M $46.67M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About URGN and 13F data

URGN (UROGEN PHARMA LTD) is a Health Care company. 44 other funds we track also report a position in URGN — the largest reported positions include RTW INVESTMENTS, LP (US$167.2M), Kynam Capital Management, LP (US$89.6M), Jefferies Financial Group Inc. (US$89.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding URGN

All URGN fund holders →

FAQ

How long has SILVERARC CAPITAL MANAGEMENT, LLC held URGN?

SILVERARC CAPITAL MANAGEMENT, LLC has disclosed URGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in URGN?

As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 1.15M shares of URGN (UROGEN PHARMA LTD), valued at $46.67M, representing 5.95% of its reported portfolio and ranking #4.

Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling URGN?

In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC reduced its position in URGN. The position peaked in Q2 2026 at 1.30M shares.

Which other funds hold URGN?

Other major institutional holders of URGN include RTW INVESTMENTS, LP, Kynam Capital Management, LP, Jefferies Financial Group Inc., among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.